Literature DB >> 11048891

CD36 and atherosclerosis.

R L Silverstein1, M Febbraio.   

Abstract

CD36 has been associated with diverse normal and pathologic processes. These include scavenger receptor functions (uptake of apoptotic cells and modified lipid), lipid metabolism and fatty acid transport, adhesion, angiogenesis, modulation of inflammation, transforming growth factor-beta activation, atherosclerosis, diabetes and cardiomyopathy. Although CD36 was identified more than 25 years ago, it is only with the advent of recent genetic technology that in-vivo evidence has emerged for its physiologic and pathologic relevance. As these in-vivo studies are expanded, we will gain further insight into the mechanism(s) by which CD36 transmits a cellular signal, and this will allow the design of specific therapeutics that impact on a particular function of CD36.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11048891     DOI: 10.1097/00041433-200010000-00006

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  44 in total

1.  Plasmodium yoelii sporozoites infect CD36-deficient mice.

Authors:  Photini Sinnis; Maria Febbraio
Journal:  Exp Parasitol       Date:  2002-01       Impact factor: 2.011

Review 2.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  S100 proteins in cartilage: role in arthritis.

Authors:  Raghunatha R Yammani
Journal:  Biochim Biophys Acta       Date:  2012-01-12

4.  Diabetes insipidus contributes to traumatic brain injury pathology via CD36 neuroinflammation.

Authors:  Theo Diamandis; Chiara Gonzales-Portillo; Gabriel S Gonzales-Portillo; Meaghan Staples; Mia C Borlongan; Diana Hernandez; Sandra Acosta; Cesar V Borlongan
Journal:  Med Hypotheses       Date:  2013-08-30       Impact factor: 1.538

5.  COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells.

Authors:  Kamran Anwar; Iryna Voloshyna; Michael J Littlefield; Steven E Carsons; Peter A Wirkowski; Nadia L Jaber; Andrew Sohn; Sajan Eapen; Allison B Reiss
Journal:  Lipids       Date:  2010-12-22       Impact factor: 1.880

6.  CD36 and proteoglycan-mediated pathways for (n-3) fatty acid enriched triglyceride-rich particle blood clearance in mouse models in vivo and in peritoneal macrophages in vitro.

Authors:  Narumon Densupsoontorn; Yvon A Carpentier; Radjini Racine; Faith M Murray; Toru Seo; Rajasekhar Ramakrishnan; Richard J Deckelbaum
Journal:  J Nutr       Date:  2008-02       Impact factor: 4.798

7.  Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.

Authors:  Björn Gustafsson; Susan Youens; Angelique Y Louie
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

8.  Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2.

Authors:  Maximiliano J Jimenez-Dalmaroni; Nengming Xiao; Adam L Corper; Petra Verdino; Gary D Ainge; Dave S Larsen; Gavin F Painter; Pauline M Rudd; Raymond A Dwek; Kasper Hoebe; Bruce Beutler; Ian A Wilson
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

9.  Positive association of common variants in CD36 with neovascular age-related macular degeneration.

Authors:  Naoshi Kondo; Shigeru Honda; Shin-Ichi Kuno; Akira Negi
Journal:  Aging (Albany NY)       Date:  2009-02-12       Impact factor: 5.682

10.  Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis.

Authors:  Ashwani K Khanna
Journal:  J Biomed Sci       Date:  2009-07-15       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.